Categories: HealthcareNews

Axonics to Present at the J.P. Morgan Healthcare Conference

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.


Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website.

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times list of the fastest growing companies in the Americas after being ranked No. 1 in 2022.

Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.

Contacts

Neil Bhalodkar

949-336-5293

IR@axonics.com

Staff

Recent Posts

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

2 hours ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

2 hours ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

2 hours ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

2 hours ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

3 hours ago